| abstract |
Describes the solid pharmaceutical dosage form of HIV protease inhibitors, providing improved oral bioavailability. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor, and at least one pharmaceutically acceptable water-soluble polymer, and at least one pharmaceutically acceptable surfactant, and the specified pharmaceutically acceptable water-soluble polymer has a Tg of at least about 50 ° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. |